Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: Application to treatment of acute ischemic stroke

Journal of Clinical Epidemiology

Volumn 52, Issue 3, 1999, Pages 259-271

  Samsa, Gregory P ^a,b   Reutter, Richard A ^a   Parmigiani, Giovanni ^a   Ancukiewicz, Marek ^a   Abrahamse, Paul ^a   Lipscomb, Joseph ^a   Matchar, David B ^a,b  

^a DUKE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cost effectiveness analysis; Simulation modeling; Stroke treatment

Indexed keywords

ARTICLE; BRAIN ISCHEMIA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE POLICY; HEALTH CARE QUALITY; MEDICAL DECISION MAKING; PHYSICAL DISABILITY; PRIORITY JOURNAL; SIMULATION; STROKE; SURVIVAL;

ACUTE DISEASE; BRAIN ISCHEMIA; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISABILITY EVALUATION; HUMANS; MODELS, ECONOMIC; MONTE CARLO METHOD; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

EID: 0032977651     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(98)00151-6     Document Type: Article

References (48)

1. National Stroke Association. Stroke/Brain Attack Briefing. Englewood, CO: National Stroke Association; 1994.
2. Matchar D.B., Duncan P.W. Cost of stroke. Stroke Clin Updates. 5(3):1994;9-12.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587.
4. Luce B.R., Manning W.G., Siegel J.E., Lipscomb J. Estimating costs in cost-effectiveness analysis. Gold M., Siegel J., Weinstein M.C., Russell L. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York, NY.
5. Matchar D.B., Duncan P.W., Samsa G.P., Whisnant J.P., DeFriese G.H., Ballard D.J.et al. The stroke prevention patient outcomes research team. Goals and methods Stroke. 24:1993;2135-2142.
6. Parmigiani G., Ancukiewicz M., Matchar D. Decision models in clinical recommendations development. The stroke prevention policy model Berry D.A., Stangl D.K. Bayesian Biostatistics. 1996;Marcel Dekker, Inc, New York, NY.
7. Matchar D.B., Samsa G.P., Matthews J.R., Ancukiewicz M., Parmigiani G., Hasselblad V.et al. The stroke prevention policy model (SPPM). Linking evidence and clinical decisions Ann Intern Med. 127:1997;704-711.
8. Parmigiani G., Samsa G.P., Ancukiewicz M., Lipscomb J., Hasselblad V., Matchar D.B. Assessing uncertainty in cost-effectiveness analyses. Application to a complex decision model Med Decision Making. 17:1997;390-401.
9. Lipscomb J., Weinstein M.C., Torrance G.W. Time preference. Gold M., Siegel J., Weinstein M.C., Russell L. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York, NY.
10. Wolf P.A., Cobb J.L., D'Agostino R.B. Epidemiology of stroke. Barnett H.J., Stein B.M., Mohr J.P., Yatsu F.M. Stroke. Pathophysiology, Diagnosis, and Management:1992;Churchill Livingstone, New York, NY.
11. Mitchell J.B., Ballard D.J., Whisnant J.P., Ammering C.J., Samsa G.P., Matchar D.B. What role do neurologists play in determining the costs and outcomes of stroke patients? Stroke. 2:1996;1937-1943.
12. Samsa G.P., Matchar D.B., Goldstein L., Bonito A., Duncan P., Lipscomb J.et al. Utilities for major stroke. Results from a survey of preferences among persons at increased risk for stroke Am Heart J. 136:1998;703-713.
13. Samsa G.P., Cohen S.J., Goldstein L.B., Bonito A.J., Duncan P.W., Enarson C.et al. Knowledge of risk among patients at increased risk for stroke. Stroke. 28:1997;916-921.
14. Rankin J. Cerebral vascular accidents in patients over age 60. 2. Prognosis. Scott Med J. 2:1957;200-215.
15. Soloman N.A., Glick H.A., Russo C.J., Lee J., Schulman K.A. Patient preferences for stroke outcomes. Stroke. 235:1994;1721-1725.
16. Gage B.F., Cardinalli A.B., Owens D.K. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 156:1996;1829-1836.
17. Feeny D., Furlong W., Boyle M., Torrance G.W. Multi-attribute health status classification systems. Health Utilities Index Pharmacoeconomics. 7:1995;490-502.
18. Duncan P.W., Goldstein L.B., Horner R.D., Landsman P.B., Samsa G.P., Matchar D.M. Similar motor recovery of upper and lower extremities after stroke. Stroke. 25:1994;1181-1188.
19. Heller A., Wade D.T., Wood V.A., Sunderland A., Langton-Hewer R., Ward E. Arm function after stroke. Measurement and recovery over the first three months J Neurol Neurosurg Psychiatry. 50:1987;714-719.
20. Partridge C.J., Johnston M., Edwards S. Recovery from physical disability after stroke. normal patterns as a basis for evaluation Lancet. 1:1987;373-375.
21. Parker V.M., Wade D.T., Langton-Hewer R. Loss of arm function after stroke. Measurement, frequency, and recovery Int Rehabil Med. 8:1986;69-73.
22. Wade D.T., Langton-Hewer R., Wood V.A., Skilbeck C.E., Ismail H.M. The hemiplegic arm after stroke. Measurement and recovery J Neurol Neurosurg Psychiatry. 48:1985;7-13.
23. Skilbeck C.E., Wade D.T., Hewer R.L., Wood V.A. Recovery after stroke. J Neurol Neurosurg Psychiatry. 46:1983;5-8.
24. Bonita R., Beaglehole R. Recovery of motor function after stroke. Stroke. 19:1988;1497-1500.
25. Katz S., Ford A.B., Chinn A.B., Newill V.A. Prognosis after strokes. Part II. Long-term course of 159 patients Medicine (Baltimore). 45:1966;236-246.
26. Andrews K., Brocklehurst J.C., Richards B., Laycock P.J. The rate of recovery from stroke and its measurement. Int Rehabil Med. 3:1981;155-161.
27. Ahlsio B., Britton M., Murray V., Theorell T. Disablement and quality of life after stroke. Stroke. 15:1984;886-890.
28. Kotila M., Waltimo O., Niemi M.L., Laaksonen R., Lempinen M. The profile of recovery from stroke and factors influencing outcome. Stroke. 15:1984;1039-1044.
29. Dombovy M.L., Basford J.R., Whisnant J.P., Bergstralh E.J. Disability and use of rehabilitation services following stroke in Rochester, Minnesota, 1975-1979. Stroke. 18:1987;830-836.
30. Leibson C.L., Hu T. Utilization of acute services in the year before and after first stroke. a population-based study Neurology. 46(3):1996;861-869.
31. Hass U., Persson J., Brodin H., Freden-Karlsson I., Olsson J.E. Assessment of rehabilitation technologies in stroke. Outcomes and costs Int J Technol Asses Health Care. 11:1995;245-261.
32. Brown RD, Leibson CL, Ransom J, Hass S, Petty GW, O'Fallon WM, et al. Utilization of nursing home following stroke: a population-based analysis in Rochester, Minnesota. Presented at 22nd International Joint Conference of Stroke and Cerebral Circulation, February 6-8, 1997, Anaheim, California. (Abstract).
33. Derdeyn C.P., Powers W.J. Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease. Stroke. 27:1996;1944-1950.
34. Laupacis A., Feeny D., Detsky A.S., Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 146:1992;473-481.
35. Manning W.G., Fryback D.G., Weinstein M.C. Reflecting uncertainty in cost-effectiveness analysis. Gold M., Siegel J., Weinstein M.C., Russell L. Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York.
36. Stinnett A. Adjusting for bias in c/e ratio estimates. Health Econ. 5:1996;470-472.
37. Chaudhary M.A., Stearns S.C. Estimating confidence intervals for cost-effectiveness ratios. An example from a randomized trial Stat Med. 15:1996;1447-1458.
38. Mullahy J., Manning W.G. Statistical issues in cost-effectiveness analysis. Sloan F. Valuing Health Care. Costs, Benefits and Effectiveness of Pharmaceuticals and Other Medical Technologies:1994;Cambridge University Press, New York.
39. O'Brien B.J., Drummond M.F., Labelle R.J., Willan A. In search of power and signfiicance. Issues in the design and analysis of stochastic cost-effectiveness studies in health care Med Care. 32:1994;150-163.
40. Laska E.M., Meissner M., Siegel C. Statistical inference for cost-effectiveness ratios. Health Econ. 6:1997;229-242.
41. vanHout B.A., Al M.J., Gordon G.S., Rutten F.F.H. Costs, effects and c/e-ratios alongside a clinical trial. Health Econ. 3:1994;309-319.
42. Willan A.R., O'Brien B.J. Confidence intervals for cost-effectiveness ratios. An application of Fieller's theorem Health Econ. 5:1996;297-305.
43. Dittus R.S., Roberts S.D., Adolph R.J. Cost-effectiveness analysis of patient management alternatives after uncomplicated myocardial infarction. a model J Am Coll Cardiol. 10:1987;869-878.
44. Mark D.B., Hlatky M.A., Califf R.M., Naylor C.D., Lee K.L., Armstrong P.W.et al. Cost-effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 332:1995;1418-1424.
45. Tosteson A.N.A., Rosenthal D.I., Melton J., Weinstein M.C. Cost-effectiveness of screening perimenopausal white women for osteoporosis. Bone densitometry and hormone replacement therapy Ann Intern Med. 113:1990;594-603.
46. Eddy D.M. Screening for Cancer. Theory, Analysis, and Design:1980;Prentice-Hall Inc, Englewood Cliffs, NJ.
47. Weinstein M.C., Coxson P.G., Williams L.W., Pass T.M., Stason W.B., Goldman L. Forecasting coronary heart disease incidence, mortality, and cost. The Coronary Heart Disease Policy Model Am J Public Health. 77:1987;1417-1426.
48. Weinstein M.C. Methodologic issues in policy modeling for cardiovascular disease. J Am Coll Cardiol. 14:1989;38A-43A.